

Targeting of Aberrant $\alpha v\beta 6$ Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

Lynsey M. Whilding, Ana C. Parente-Pereira, Tomasz Zabinski, David M. Davies, Roseanna M.G. Petrovic, Y. Vincent Kao, Shobhit A. Saxena, Alex Romain, Jose A. Costa-Guerra, Shelia Violette, Hiroaki Itamochi, Sadaf Ghaem-Maghami, Sabari Vallath, John F. Marshall, and John Maher

Correspondence: john.maher@kcl.ac.uk (J.M.)
<http://dx.doi.org/10.1016/j.ymthe.2017.09.018>

(Molecular Therapy 25, 259–273; January 4, 2017)

The authors regret that King's Health Partners Confidence in Concept was inadvertently omitted as a funding source in the Acknowledgments section of the original paper. The corrected Acknowledgments section appears below and has been corrected online. We apologize for any inconvenience this may have caused.

ACKNOWLEDGMENTS

This research was supported by Worldwide Cancer Research (13- 1017), Breast Cancer Now (2010MayPR33), Pancreatic Cancer UK (A16648), King's Health Partners Confidence in Concept (MC_PC_14105), the Experimental Cancer Medicine Centre at King's College London, and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We thank Anthony Walker and Mike Garrison for useful discussions.